Retatrutide, a new dual stimulator of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) receptor , is showing promising outcomes in preliminary clinical assessments . Recent https://express-page.com/story6833166/retatrutide-emerging-studies-and-potential-therapeutic-applications